ADmit Therapeutics, S.L. is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), and focused on the development and commercialization of a novel Alzheimer's disease (AD) early detection technology.
Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau.
Our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.
ADmit Therapeutics obtains the support of the Alzheimer’s Drug Discovery Foundation (ADDF) to develop its early Alzheimer’s diagnostic test
ADmit Therapeutics has received an investment of 497.652$ from the ADDF Diagnostics Accelerator for the development of its early Alzheimer’s disease diagnostic test in blood samples. The Diagnostics Accelerator is a research initiative that seeks to accelerate the development of affordable and accessible biomarkers to diagnose Alzheimer's disease ...
CO-FOUNDER Ramón ReñéCHIEF MEDICAL OFFICER
MD, PhD in Medicine and Surgery
(Autonomous University of Barcelona) Jordi GascónCHIEF SCIENTIFIC OFFICER
MD in Medicine and Surgery
(Autonomous University of Barcelona)
This website uses our own cookies and third-party cookies to collect information, in order to improve our services. Your continued use of this website constitutes acceptance of the installation of these cookies. The user has the option of configuring their browser in order to prevent cookies from being installed on their hard drive, although they must keep in mind that doing so may cause difficulties in their use of the webpage. I AgreeHow to configure browser